QM · rank #7 · 2026-09-09
LQDA
NASDAQ · $6.14B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +345.13% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +131.8% |
| Profit margin Net profit margin, trailing 12 months. | +30.7% |
| Market cap (USD) Size filter: > $500M required. | $6.14B |
| Anchor (recent) Close on 2026-08-10 | $91.03 |
| Anchor (far) Close on 2025-08-08 | $20.45 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a focused rare cardiopulmonary biopharma commercializing YUTREPIA, a dry-powder inhaled treprostinil for PAH and PH-ILD, which generated $170.4M in net product sales in Q2 2026 alone.
Rationale
The quality_momentum signal is strongly reinforced by four consecutive quarters of rising profitability, 31% sequential revenue growth, a 30%+ profit margin, and an ROE above 1.3x on a business that was essentially pre-revenue a year ago — exactly the kind of accelerating fundamental inflection this strategy targets.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, label restriction, or a competing inhaled treprostinil formulation from a larger PAH player (e.g., United Therapeutics) could collapse the revenue base with no offset.
- 2Reimbursement and payer pressure on a high-cost specialty therapy could compress net pricing and slow prescriber adoption, directly threatening the margin trajectory that underpins the quality signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.